Introduction {#Sec1}
============

As the global demand for energy continues to rise, biofuels derived from renewable sources have become increasingly important. Currently, most of the emphasis in biofuels is on bio-ethanol as there is a long history for its production (Chandrakant and Bisaria [@CR5]; Galbe and Zacchi [@CR13]; Jarboe et al. [@CR17]). However, increasing attention is being paid to higher alcohols (Miller et al. [@CR20]; Atsumi et al. [@CR1],[@CR2]) as the potential for a direct replacement of gasoline. Those alcohols have four to five carbons and possess a host of qualities making them more suitable as a liquid fuel than ethanol, including lower vapor pressure, lower hygroscopicity, and higher energy density.

Since the gasoline we use today consists of a finely tuned mixture of components, it is likely that the next-generation fuel to replace gasoline will also be a mixture and the five carbon alcohol 2-methyl-1-butanol (2MB), also known as active amyl alcohol, is likely to be an important component. Previously, 2MB has been considered a minor byproduct found in beer, wine, and other fermented beverages. This is due to the presence of several pyruvate decarboxylase (PDC) enzymes found in the yeast, *Saccharomyces cerevisiae*, used to ferment these alcoholic beverages, some of which are able to catalyze the decarboxylation of 2-ketoacids larger than pyruvate, especially those 2-ketoacids involved in branched-chain amino acid synthesis (Dickinson et al. [@CR9], [@CR10], [@CR11]). PDC converts these 2-ketoacids into aldehydes, which are then reduced to alcohols in one further step using an alcohol dehydrogenase (ADH) enzyme. Until recently (Atsumi et al. [@CR2]), the utility of these higher alcohols as biofuels has not been fully realized. No report has demonstrated the overproduction of 2MB from glucose in a microorganism.

The production of higher alcohols from amino acid precursors in *Escherichia coli* has proven to be promising (Atsumi et al. [@CR2]; Shen and Liao [@CR23]; Connor and Liao [@CR6]). Because it exploits the host's native amino acid synthesis pathways, this approach can be implemented in a variety of hosts to produce the desired products. The biosynthetic pathways of the branched-chain amino acids produce at least four natural 2-ketoacids that can be converted to potentially useful higher alcohols (Atsumi et al. [@CR2]). Here, we utilize the isoleucine biosynthetic pathway in particular to synthesize 2-keto-3-methylvalerate (KMV), which is then converted to 2MB via a promiscuous 2-ketoacid decarboxylase (KDC) and ADH (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Pathway for 2-methyl-1-butanol synthesis and important side products. *Genes in bold* are overexpressed in our system while *underlined genes* are knocked out. *PEP* phosphoenolpyruvate, *KIV* keto-isovalerate, *OAA* oxaloacetic acid, *αKG* α-keto-glutarate, *2KB* 2-ketobutyrate, *AHB* 2-aceto-2-hydroxybutyrate, *KMV* 2-keto-3-methylvalerate

In *E. coli*, KMV is derived from threonine, which in turn is part of the aspartate family of amino acids. The production of KMV from glucose involves ten enzymatic reactions from the glycolytic product phosphoenolpyruvate (PEP). From PEP, aspartate is produced from the products of two genes, *ppc* and *aspC* (Fig. [1](#Fig1){ref-type="fig"}). Only four genes, *asd* and the *thrABC* operon, are required to complete the five reactions to produce threonine from aspartate. The deamination of threonine to 2-ketobutyrate (2KB) can be catalyzed by the products of either one of two genes, *ilvA* and *tdcB*, encoding a biosynthetic and catabolic threonine deaminase, respectively. The condensation of 2KB and pyruvate to 2-aceto-2-hydroxybutyrate is catalyzed by acetohydroxy acid synthase (AHAS), an enzyme which also catalyzes the first step in valine production. Two more genes, *ilvC* and *ilvD*, are necessary for the formation of KMV, the penultimate precursor in 2MB synthesis. In the cell, KMV is normally converted to isoleucine with transamination carried out by transaminase B encoded by *ilvE*.

With the utilization of the isoleucine production pathway in the formation of 2MB, there is a lot of previous work to draw upon on the overproduction of isoleucine in various organisms. It has been shown that overexpression of *ilvD* is important to prevent the buildup of 2,3-dihydroxy-3-methylvalerate (Hashiguchi et al. [@CR16]), the immediate precursor to KMV. For the condensation of 2KB and pyruvate, there are multiple AHAS enzymes to consider, three in *E. coli* alone, but each has slightly different properties making it more conducive for either valine or isoleucine production, of which we of course prefer the latter. Of the three isozymes found in *E. coli*, AHAS II encoded by *ilvGM* would likely be the best for isoleucine production were it not for a frameshift mutation rendering it inactive in K-12-derived strains (Favre et al. [@CR12]). Nonetheless, enzyme kinetic data show that AHAS II from *E. coli* and several other enteric bacteria provides a greater ratio of 2-aceto-2-hydroxybutryate to 2-acetolactate formation than the other AHAS isozymes (Barak et al. [@CR4]; Gollop et al. [@CR14]), suggesting that AHAS II should be the best isozyme for isoleucine production. In research on *Corynebacterium glutamicum*, it was shown that a lysine-producing strain could be converted to isoleucine production with the overexpression of only three key genes: a feedback resistant *hom* (equivalent to *thrA* in *E. coli*), *thrB*, and feedback resistant *ilvA* (Morbach et al. [@CR22]). Overexpressing the first gene, *thrA*, draws carbon flux away from lysine production (Fig. [1](#Fig1){ref-type="fig"}), while overexpression of *thrB* draws carbon flux away from methionine. The third gene, *ilvA*, allows for the deamination of threonine to 2KB, thus feeding the AHAS enzymatic reaction.

On the basis of the prior art, this article reports the construction of an *E. coli* strain to produce 2MB from glucose. This work presents additional challenges since byproducts such as 1-propanol and isobutanol are also produced from the KDC and ADH used to produce 2MB. Furthermore, these products are toxic to the cell when present in sufficient concentrations.

Materials and methods {#Sec2}
=====================

Bacterial strains {#Sec3}
-----------------

*E. coli* BW25113 (*rrnB* ~T14~ Δ*lacZ*WJ16 *hsdR*514 Δ*araBAD* ~AH33~ Δ*rhaBAD* ~LD78~) was designated as the wild-type strain (Datsenko and Wanner [@CR7]) for this study. XL-1 Blue (Stratagene, La Jolla, CA, USA) was used to propagate all plasmids. Construction of strains CRS22 and CRS24 is described previously (Shen and Liao [@CR23]). Strain CRS38 was constructed by deleting the *leuABCD* operon as previously described (Datsenko and Wanner [@CR7]). Host gene deletions of *leuA* and *ilvE* in strains AFC16 and AFC18, respectively, were achieved with P1 transduction using the appropriate Keio collection strains (Baba et al. [@CR3]) as donors. The Kan^R^ inserted into the target gene region was removed using pCP20 (Datsenko and Wanner [@CR7]) in between each consecutive knockout. The removal of each gene segment was verified by colony polymerase chain reaction (PCR) using the appropriate primers.

Reagents, media, and cultivation {#Sec4}
--------------------------------

All restriction enzymes and Antarctic phosphatase were purchased from New England Biolabs (Ipswich, MA, USA). The Rapid DNA ligation kit was supplied by Roche (Manheim, Germany). KOD DNA polymerase was purchased from EMD Chemicals (San Diego, CA, USA). Oligonucleotides were ordered from Invitrogen (Carlsbad, CA, USA).

For all production experiments, strains were grown in a modified M9 medium (6 g Na~2~HPO~4~, 3 g KH~2~PO~4~, 1 g NH~4~Cl, 0.5 g NaCl, 1 mM MgSO~4~, 1 mM CaCl~2~, 10 mg vitamin B~1~ per liter of water) containing 15 g/L of glucose, 5 g/L of yeast extract, and 1,000× Trace Metals Mix A5 (2.86 g H~3~BO~3~, 1.81 g MnCl~2~·4H~2~O, 0.222 g ZnSO~4~·7H~2~O, 0.39 g Na~2~MoO~4~·2H~2~O, 79 mg CuSO~4~·5H~2~O, 49.4 mg Co(NO~3~)~2~·6H~2~O per liter of water). From 2 mL overnight cultures grown in LB, cultures were inoculated at 1% into 10 mL of the above modified M9 medium and were allowed to grow at 37°C in 250 mL baffled flasks to an OD~600~ of approximately 0.6 before induction with 0.1 mM IPTG. After induction, 5 mL of the cultures was transferred to 125 mL screw-cap flasks and the incubation temperature was reduced to 30°C. For the experiments where [l]{.smallcaps}-threonine or 2-ketobutyrate was added to the culture, it was added at induction to a final concentration of 8 g/L. Antibiotics were added as necessary for plasmid maintenance (ampicillin 100 μg/mL, kanamycin 50 μg/mL, and spectinomycin 50 μg/mL). All antibiotics and reagents were purchased from either Sigma-Aldrich (St. Louis, MO, USA) or Fisher Scientific (Houston, TX, USA).

Plasmid construction {#Sec5}
--------------------

The vectors pSA40, pSA54, pSA55 (Atsumi et al. [@CR2]), and pCS49 (Shen and Liao [@CR23]) were designed and constructed as described previously. The vectors expressing the various AHAS genes were built in a manner similar to pSA54, all beginning with pSA40 as the base.

Vector pKS15 began by amplifying the *ilvBN* genes from the *E. coli* MG1655 chromosome using primers IlvB-*Acc*65I-fwd and IlvNC-SOE1. The beginning of the *ilvC* gene located on pSA54 was also amplified from the *Sal*I site upstream of the RBS to the Acc65I site within the *ilvC* gene using primers IlvNC-SOE2 and IlvC-Acc65I-rev. These two fragments were then joined by splice overlap extension (SOE), creating a *ilvBNC*\* fragment with Acc65I cut sites at either end. Then pSA54 was cut with Acc65I, the large portion was gel purified, and then this backbone was ligated with the new *ilvBNC*\* fragment to create pKS15.

In order to test the expression of the protein encoded by *E. coli ilvG*, we needed to fix the frameshift present at base pair 984 in the *ilvG* gene found in *E. coli* MG1655. The sequence at the frameshift indicates a TGA stop codon within the *ilvG* reading frame, and this sequence was modified from 5′-AATCAA**TGA**CTGGCA-3′ to 5′-AATCAA**TG*TG*A**CTGGCA-3′ to recover expression of this protein. To accomplish this feat, we amplified two fragments of the genome with primers IlvG-Acc65I-fwd and TGins-*Sap*I-rev for the beginning portion of the *ilvG* gene and primers TGins-*Sap*I-fwd and IlvM-*Hin*dIII-rev for the end portion of *ilvGM*. These fragments along with pSA40 were digested with *Acc*65I, *Hin*dIII, and *Sap*I as appropriate and then ligated together to create pAFC22. To complete vector pAFC23, the backbone of pSA54 was amplified from the *ilvC* gene to the p15A origin of replication using primers IlvC-SA-*Bam*HI-fwd and P15-SA-*Sac*I-rev. This backbone was ligated to the *Sac*I--*Bam*HI fragment from pAFC22 containing the kanamycin resistance gene and *ilvGM* genes to create pAFC23.

Vectors pAFC3 and pAFC29 each began by using primers IlvG-*Acc*65I-fwd and IlvM-*Hin*dIII-rev to amplify the *ilvGM* genes from the chromosomes of *Salmonella typhimurium* LT2 and *Klebsiella pneumoniae* ATCC 700721, respectively, creating an *Acc*65I--*Hin*dIII fragment. These fragments were then ligated in the same cut sites of pSA40. From here we added the *ilvCD* genes and P15A replication origin from pSA54 in the same fashion was used for pAFC23.

Vector pAFC26 began by using primers CG-ilvB-*Cla*I-fwd and CG-ilvN-*Bam*HI-rev to amplify the *ilvBN* genes from the chromosome of *C. glutamicum* ATCC 13032 to make a *Cla*I--*Bam*HI fragment. Ligation of this fragment into the same cut sites of pSA40 introduced a new RBS downstream of the one already present. Similar to the previous three vectors, the *ilvCD* genes and P15A origin were added to complete this vector.

The vectors expressing the various threonine deaminase genes all used pSA55 as a base. From the *E. coli* MG1655 chromosome, *tdcB* (pAFC8) and *ilvA* (pAFC45) were amplified using primers TdcB-*Xba*I-fwd/rev and IlvA-*Xba*I-fwd/rev, respectively. From the *C. glutamicum* chromosome *ilvA* (pAFC46) was amplified using primers CG-ilvA-*Xba*I-fwd/rev. Amplification of each of these three genes resulted in DNA fragments with *Xba*I cut sites at each end. These fragments were then ligated into the *Xba*I cut site directly behind the ADH2 gene on pSA55 and orientation was confirmed by PCR and by restriction digest.

All vectors were sequenced using the appropriate primers to verify sequence fidelity.

Metabolite detection {#Sec6}
--------------------

The produced alcohol compounds were quantified by a gas chromatograph (GC) equipped with flame ionization detector (FID). The system consisted of model 5890A GC (Hewlett Packard, Avondale, PA, USA) and a model 7673A automatic injector, sampler and controller (Hewlett Packard). The separation of alcohol compounds was carried out by A DB-WAX capillary column (30 m, 0.32 mm-i.d., 0.50 μm film thickness) purchased from Agilent Technologies (Santa Clara, CA, USA). GC oven temperature was initially held at 40°C for 2 min and raised with a gradient of 5°C/min for 1 min, then held at 45°C for 4 min, then raised again with a gradient of 15°C/min until 190°C. At this point, the temperature was raised with a gradient 50°C/min until 230°C and held for 4 min to clear the column of any remaining chemicals. Helium was used as the carrier gas with 9.0 psi inlet pressure. The FID was fed by a mixture of hydrogen, air, and helium. The injector and detector were maintained at 225°C. The column was injected with 0.5 μL of the supernatant of culture broth in a split injection mode with a 1:15 split ratio. The internal standard used was 1-pentanol, and alcohol content was determined by extrapolation from standard curves using the internal standard to normalize the values.

Results {#Sec7}
=======

Selection of AHAS {#Sec8}
-----------------

Our lab has previously shown 2MB formation from glucose in *E. coli* (Atsumi et al. [@CR2]). In order to increase 2MB production, it was important to first overexpress the enzymes that would boost its production. The first committed reaction in 2MB synthesis is the condensation of 2KB and pyruvate to form 2-aceto-2-hydroxybutyrate. As this reaction can be catalyzed by several different types of AHAS enzyme, we compared a number of these AHAS (Table [1](#Tab1){ref-type="table"}) to select one most suitable for 2MB production. Table 1Comparison of AHAS specificity for 2KB in synthesis of 2MBIsozymeGenesOrganism2-Methyl-1-butanol1-PropanolTotal alcohol conversion^a^ (%)Titer (mM)Conversion^a^ (%)Titer (mM)Conversion^a^ (%)AHAS III*ilvIHE. coli*22.4 ± 0.82933.3 ± 5.04371AHAS II*ilvGME. coli*24.0 ± 2.53138.2 ± 3.44979*S. typhimurium*36.7 ± 0.24730.0 ± 0.93885*K. pneumoniae*26.9 ± 0.13435.4 ± 0.54580AHAS I*ilvBNE. coli*1.29 ± 0.691.647.5 ± 5.06162*C. glutamicum*13.1 ± 3.01743.7 ± 2.85673Data shown are the average of at least three different experiments. Wild-type cells were grown in modified M9 medium as described in "[Materials and methods](#Sec2){ref-type="sec"}". Cultures were induced with 0.1 mM IPTG, and at the same time, 2-ketobutyrate was added to a final concentration of 8 g/L. Samples were taken 16 h after induction.^a^Conversion given as molar conversion from the 2-ketobutyrate added at induction

To test the efficacy of these AHAS isozymes, we replaced *ilvIH* from pSA54 with other genes encoding AHAS (Table [2](#Tab2){ref-type="table"}) in a cassette fashion to ensure that each enzyme would be expressed similarly. We combined these AHAS plasmids with pSA55, which expresses the KDC and ADH necessary to convert KMV from the isoleucine pathway into 2MB, in a BW25113 host. Since the KDC expressed from pSA55 is able to decarboxylate a broad range of 2-ketoacids (de la Plaza et al. [@CR8]; Atsumi et al. [@CR2]), the KDC and AHAS would compete for 2KB in the cell. If KDC outcompetes AHAS for 2KB, 1-propanol will be produced instead of 2MB. To test the selectivity, we added 0.8% *w*/*v* 2KB to the production medium and measured 2MB and 1-propanol production. Table 2Strains and plasmids used in this studyNameRelevant genotypeReferenceStrains BW25113*rrnB* ~T14~ Δ*lacZ*WJ16 *hsdR514* Δ*araBAD* ~AH33~ Δ*rhaBAD* ~LD78~Datsenko and Wanner ([@CR7]) XL-1 Blue*recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac* \[F′ *proAB lacI* ^q^*Z*Δ*M15* Tn*10* (Tet^R^)\]Stratagene CRS22BW25113 F′ Δ*metA* Δ*tdh*Shen and Liao ([@CR23]) CRS24BW25113 F′ Δ*metA* Δ*tdh* Δ*ilvB* Δ*ilvI*Shen and Liao ([@CR23]) CRS38BW25113 F′ Δ*metA* Δ*tdh* Δ*ilvB* Δ*ilvI* Δ*leuABCD*This study AFC16BW25113 F′ Δ*metA* Δ*tdh* Δ*leuA*This study AFC18BW25113 F′ Δ*metA* Δ*tdh* Δ*leuA* Δ*ilvE*This studyPlasmids pSA40ColE1 ori, Amp^R^, P~L~lacO~1~::MCSAtsumi et al. ([@CR2]) pSA54p15A ori, Kan^R^, P~L~lacO~1~::*ilvIHCD*Atsumi et al. ([@CR2]) pSA55ColE1 ori, Amp^R^, P~L~lacO~1~::*kivd ADH2*Atsumi et al. ([@CR2]) pKS15p15A ori, Kan^R^, P~L~lacO~1~::*ilvBNCD* (from *E. coli*)This study pCS49From pSA40, pSC101 ori, Spec^R^, P~L~lacO~1~::*thrABC* from *E. coli*Shen and Liao ([@CR23]) pAFC3p15A ori, Kan^R^, P~L~lacO~1~::*ilvGMCD* (*ilvGM* from *S. typhimurium*)This study pAFC8pSA55 with *tdcB* from *E. coli* in *Xba*I cut siteThis study pAFC23p15A ori, Kan^R^, P~L~lacO~1~::*ilvGMCD* (from *E. coli*)This study pAFC26p15A ori, Kan^R^, P~L~lacO~1~::*ilvBNCD* (*ilvBN* from *C. glutamicum*)This study pAFC29p15A ori, Kan^R^, P~L~lacO~1~::*ilvGMCD* (*ilvGM* from *K. pneumoniae*)This study pAFC45pSA55 with *ilvA* from *E. coli* in *Xba*I cut siteThis study pAFC46pSA55 with *ilvA* from *C. glutamicum* in *Xba*I cut siteThis studyPrimers IlvB-*Acc*65I-fwd5′-GC**GGTACC**ATGGCAAGTTCGGGCACAACATC-3′ IlvNC-SOE15′-CAGTGTATTGAAGTAGTTAGCCATGGTGATTCCTCGTCGACTTTACTGAAAAAAC-ACCGCGATCTTGTTAAAC-3′ IlvNC-SOE25′-CGCGGTGTTTTTTCAGTAAAGTCGACGAGGAATCACCATGGCTAACTACTTCAAT-ACAC-3′ IlvC-*Acc*65I-rev5′GC**GGTACC**TTCTTCCACCAGCTTGTCGAAGCAC-3′ IlvG-*Acc*65I-fwd5′-ATTA**GGTACC**ATGAACGGGGCACAGTGGGTG-3′ IlvM-*Hin*dIII-rev5′-AATT**AAGCTT**CTCAGGCGCGGATTTGTTGTG-3′ TGins-*Sap*I-fwd5′-GCATC**GCTCTTC**TGTGACTGGCAGCAACACTGC-3′ TGins-*Sap*I-rev5′-GCATC**GCTCTTC**TCACATTGATTTAACGGCTGCTGTAATG-3′ IlvC-SA-*Bam*HI-fwd5′-TTAA**GGATCC**GAGGAATCACCATGGCTAACTACTTC-3′ P15-SA-*Sac*I-rev5′-TTCGA**GAGCTC**GCTTGGACTCC-3′ TdcB-*Xba*I-fwd5′-AATT**TCTAGA**TCAGGCGAAGAGGTTTTATAATGC-3′ TdcB-*Xba*I-rev5′-AATT**TCTAGA**TTAAGCGTCAACGAAACCGG-3′ IlvA-*Xba*I-fwd5′-TTAA**TCTAGA**[AGGAGA]{.ul}TATAGCATGGCTGACTCGCAACCCC-3′ IlvA-*Xba*I-rev5′-AATT**TCTAGA**CTAACCCGCCAAAAAGAACCTG-3′ CG-ilvB-*Cla*I-fwd5′-TTAA**ATCGAT**[AGGAGA]{.ul}TATACCGTGAATGTGGCAGCTTCTCAACAG-3′ CG-ilvN-*Bam*HI-rev5′-ATTA**GGATCC**GTTTAGATCTTGGCCGGAGCC-3′ CG-ilvA-*Xba*I-fwd5′-TTAA**TCTAGA**[AGGAGA]{.ul}TATACCATGAGTGAAACATACGTGTCTGAGAAA-3′ CG-ilvA-*Xba*I-rev5′-AATT**TCTAGA**TTAGGTCAAGTATTCGTACTCAGGGG-3′

The AHAS II from *S. typhimurium* produced the highest amount of 2MB and is the only AHAS that led to higher selectivity of 2MB production versus 1-propanol. AHAS III from *E. coli* also produced a significant amount of 2MB, but could not outcompete KDC for 2KB, thus 1-propanol production was even higher. While AHAS I is used in isoleucine production in *C. glutamicum*, this isozyme did not fare well in 2MB production in *E. coli*, though it performed much better than the AHAS I from *E. coli*. The conversion rate of 2KB to 2MB is very low for *E. coli* AHAS I compared to the other isozymes. Since this enzyme is a poor consumer of 2KB, the high 2KB concentration became poisonous to the cells (LaRossa and Van Dyk [@CR18]). Not only does *S. typhimurium* AHAS II outcompete the KDC for 2KB, but it also outperforms other competing enzymes for 2KB consumption, making this enzyme the clear favorite among those tested here.

Selection of threonine deaminase {#Sec9}
--------------------------------

After the AHAS enzyme, the next important enzyme target for overexpression is the threonine deaminase. As shown previously, threonine deaminase overexpression effectively draws carbon flux towards the isoleucine pathway (Morbach et al. [@CR22]). In *E. coli*, there exists both a biosynthetic (encoded by *ilvA*) and a catabolic (encoded by *tdcB*) threonine deaminase. The biosynthetic deaminase is susceptible to feedback inhibition by isoleucine (Umbarger [@CR25]), while the catabolic deaminase is not, though it can be inhibited by high 2KB concentrations (Shizuta et al. [@CR24]). We also compared *ilvA* from *C. glutamicum*, though it, too, is inhibited by isoleucine (Möckel et al. [@CR21]).

In a similar fashion as the AHAS comparison, to test these threonine deaminases we inserted each of the three genes into pSA55 in a cassette fashion. As a control we used pSA55, which contains no threonine deaminase gene, and compared this to the effect of the overexpression of threonine deaminase. We then combined these plasmids with pAFC3, containing the genes encoding *S. typhimurium* AHAS II as determined from the previous experiment, in the same BW25113 host background. We added 0.8% *w*/*v*[l]{.smallcaps}-threonine to the production medium to study the efficiency of [l]{.smallcaps}-threonine deamination by the various isozymes and measured the alcohol production profiles in each case (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Comparison of threonine deaminase efficiency in 2MB production. Wild-type cells expressing pAFC3 and either pSA55 (no deaminase overexpression), pAFC8 (*E. coli tdcB*), pAFC45 (*E. coli ilvA*), or pAFC46 (*C. glutamicum ilvA*) were supplied with 8 g/L [l]{.smallcaps}-threonine. Samples were taken 16 h after induction. Conversion is given as molar conversion from the supplied [l]{.smallcaps}-threonine. Data shown are the average of at least three independent experiments

Overexpression of each of the threonine deaminase isozymes results in a greater conversion of [l]{.smallcaps}-threonine to 2MB and 1-propanol compared to chromosomal deaminase activity. This is in agreement with previous data suggesting greater isoleucine production with overexpression of threonine deaminase. The increased expression of *E. coli* biosynthetic deaminase (*ilvA*) only increased conversion from about 38% to about 45%, while increasing expression of the catabolic deaminase from *E. coli* (*tdcB*) converted 62% of the supplied [l]{.smallcaps}-threonine. However, the best isozyme tested was the *C. glutamicum* threonine deaminase, the overexpression of which converted nearly 88% of the supplied [l]{.smallcaps}-threonine to 2MB and 1-propanol.

Overproduction of the threonine pathway {#Sec10}
---------------------------------------

One further part of the pathway that would be important to amplify is the formation of threonine from OAA. This transformation occurs in six enzymatic reactions, but previous results (Morbach et al. [@CR22]) indicate that the steps governed by *thrA* and *thrB* are the most important. The products of these two genes lie at important branch points in the aspartate family of amino acids (Fig. [1](#Fig1){ref-type="fig"}), with *thrA* drawing carbon flux away from lysine production and *thrB* drawing carbon flux away from methionine. The *thrA* gene product also catalyzes the first step in the conversion of aspartate to isoleucine. In *E. coli*, *thrABC* is situated in one operon and so we cloned this operon into a low copy number vector in pCS49, removing the native transcription attenuation. Combined with the plasmids determined in the earlier experiments, pAFC46 (KDC, ADH, threonine deaminase) and pAFC3 (AHAS II, *ilvCD*), we performed 16-h production experiments comparing the effect of adding this threonine operon on 2MB production in (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Effect of *thr* operon overexpression on 2-methyl-1-butanol production. Wild-type cells expressing pAFC3 and pAFC46 with and without pCS49 (*thrABC*) are shown. Samples were taken 16 h after induction. Data shown are the average of at least three independent experiments

In wild-type background with only chromosomal expression of *thrABC*, isobutanol is the major product, as there is not enough 2KB being produced for sufficient 2MB production. Addition of the threonine operon plasmid doubles the 2MB production from 5.5 to 11 mM, while nearly cutting isobutanol production in half from 21 to 11.5 mM. The formation of 1-propanol also triples from 1.9 to 5.8 mM, which though in itself is not desirable, shows that much more 2KB is being generated in the cultures. In fact, the decrease in isobutanol (9.5 mM) is almost entirely accounted for in the increase of both 2MB and 1-propanol (9.4 mM), indicating that the effect of *thrABC* overexpression is to pull carbon flux away from pyruvate and towards 2KB.

Gene deletion to attenuate product specificity {#Sec11}
----------------------------------------------

Upon determining a useful set of enzymes for overexpression to boost 2MB production, we looked to gene knockouts to further increase 2MB production and yield while reducing side product formation. The first two knockouts upstream of 2KB production, Δ*metA*, for elimination of carbon flux to methionine production, which diverts the flux away from threonine, and Δ*tdh*, for reduction of competing threonine consumption, are directed at improving the carbon flux towards 2KB. From this double knockout strain we took two paths towards reducing the alcohol side products made. The first path involved removing the competing native AHAS isozymes that contribute to isobutanol formation, and these are encoded by *ilvI* and *ilvB*. The second approach began with eliminating the two peripheral side products, 1-butanol and 3-methyl-1-butanol, by deletion of *leuA*, which encodes the enzyme catalyzing the first committed step in the formation of these two alcohols. This strain was further engineered by removing *ilvE* in the hopes of reducing the amount of isoleucine created from the KMV produced. The full results of these gene knockouts are shown in Fig. [4](#Fig4){ref-type="fig"}. Each strain shown in Fig. [4](#Fig4){ref-type="fig"} contains the three plasmids (pAFC3, pAFC46, pCS49) expressing all the genes that we determined were beneficial to 2MB production. Fig. 4Effect of gene knockout combinations on 2-methyl-1-butanol production. Wild-type cells and strains CRS22 (Δ*metA* Δ*tdh*), CRS24 (Δ*metA* Δ*tdh* Δ*ilvBI*), CRS38 (Δ*metA* Δ*tdh* Δ*ilvBI* Δ*leuABCD*), AFC16 (Δ*metA* Δ*tdh* Δ*leuA*), and AFC18 (Δ*metA* Δ*tdh* Δ*leuA* Δ*ilvE*) expressing pAFC3, pAFC46, and pCS49 are shown. Data shown are the average of at least three independent experiments. **a** 2MB production. **b** Isobutanol production. **c** 1-Propanol production. **d** Glucose consumption. **e** Cell density

The strain with the highest 2MB production is the Δ*metA* Δ*tdh* double knockout strain, CRS22. It seems that the deletion of just these two genes causes a large increase in 2KB produced as measured by the production of 2MB and 1-propanol. Using this metric, nearly 24 mM 2KB is converted to 2MB and 1-propanol in CRS22 as compared to only 14.5 mM in wild-type. However, much of that extra 2KB goes towards 1-propanol production as 2MB increases from 11.2 to 14.2 mM while 1-propanol increases from 3.2 to 9.6 mM.

As for additional gene deletions, the most noticeable difference is in the diverse alcohol production profiles. From strain CRS22, further deletion of *ilvB* and *ilvI* to make CRS24 eliminates the competing AHAS enzymes that contribute more to valine production than to isoleucine. While isobutanol production is reduced by one third, 2MB production is also slightly reduced by about 15% by the loss of these additional AHAS enzymes. However, CRS24 converts the same amount of total 2KB (24 mM) compared to CRS22, as the 1-propanol production rises by exactly the amount of lost 2MB. The *leuABCD* operon was then removed from CRS24 to make CRS38 in order to completely remove 1-butanol and 3-methyl-1-butanol production. While CRS38 produces a better ratio of 2MB to isobutanol and 1-propanol than the other strains tested, it also suffers from a lower overall production compared to the other strains with a much slower growth rate, and so is not clearly better than the others.

The other string of knockout strains began by deleting *leuA* directly from the double knockout CRS22 (Δ*metA* Δ*tdh*) to make AFC16 for a cleaner product profile and reduce consumption of 2KB for 1-butanol production. Unfortunately, the major effect noticed was lower total cell density compared with the parent strain. While less severe than CRS38, it seems that the deletion of *leuA* has some adverse effect on growth when combined with the plasmids used in our system. Deletion of *leuA* also removed all traces of 1-butanol and 3-methyl-1-butanol, but again this apparently did little for the production of the other alcohols. Despite these considerations, this strain converted about the same amount of 2KB (23 mM) as its parent CRS22 and also CRS24, suggesting that increasing the 2KB levels further is more important for producing more 2MB than knocking out these side product pathways. Continuing from AFC16, we next made AFC18 by removing *ilvE*, which encodes the branched-chain amino acid aminotransferase, looking to increase 2MB production by reducing the amount of isoleucine created from the KMV produced. Strangely, this deletion actually reduced 2MB somewhat but made little difference in 1-propanol and isobutanol production. It was thought that this knockout would particularly benefit 2MB due to the low *K* ~M~ value that this aminotransferase has for KMV (Lee-Peng et al. [@CR19]), but this was not the case. The *leuA* and *ilvE* knockouts do not seem to provide much benefit to 2MB production, contrary to what we thought would be the case.

To take a closer look at the production profile of 2MB and related alcohol byproducts, a more detailed time course was obtained of the wt strain and CRS22 (Δ*metA* Δ*tdh*), both containing production plasmids pAFC3, pAFC46, and pCS49 (Fig. [5](#Fig5){ref-type="fig"}). From this figure, it becomes more obvious that production of 2MB is closely tied to the growth phase. Formation of 1-propanol develops as the 2MB production slows, and this negatively impacts 2MB yields. Fig. 5Detailed time course of strains containing the three production plasmids pAFC3, pAFC46, and pCS49. **a** BW25113 wt strain. **b** CRS22 (Δ*metA* Δ*tdh*) strain

Discussion {#Sec12}
==========

We successfully engineered the first strain of *E. coli* to produce the fuel alcohol 2MB to a final level of 1.25 g/L in 24 h and a total alcohol content of over 3 g/L with a yield of up to 0.17 g 2MB per gram glucose, which is 44% of the maximum theoretical yield. Much of the success of producing 2MB is due to the use of the host's native isoleucine biosynthetic pathway to synthesize KMV, the 2-ketoacid precursor of both isoleucine and 2MB. Earlier work in producing isoleucine from glucose in *E. coli* has produced yields of up to 0.25 g/g (Hashiguchi et al. [@CR16]), or 0.35 mol/mol. This is similar to what our strains CRS22 (0.32 mol/mol), CRS24 (0.35 mol/mol), and AFC16 (0.34 mol/mol) achieve during the growth phase before 1-propanol production becomes prominent. It turns out that both isoleucine and 2MB share a maximum theoretical yield of 0.8 mol/mol glucose, so we can compare these molar yields head to head.

While our efforts in producing 2MB were aided by previous work in isoleucine production due to an overlap in their biosynthetic pathways, it is important to recognize the unique challenges involved in 2MB production. The first challenge comes from the bifurcated pathway from glucose to 2MB, and the need for the two precursors, pyruvate and 2KB, to be balanced for efficient 2MB production (Fig. [1](#Fig1){ref-type="fig"}). Furthermore, both of these necessary precursors lead directly to an unavoidable alcohol side product, with 2KB leading to 1-propanol formation and pyruvate leading to isobutanol formation. Additionally, each of these alcohols is toxic to the host even at fairly low levels, with 2MB in particular affecting *E. coli* growth rate at concentrations as low as 1 g/L (data not shown).

To illustrate the difference in the biosynthesis of isoleucine and 2MB, the data in Fig. [2](#Fig2){ref-type="fig"} suggest that feedback inhibition due to isoleucine is not an issue for 2MB production. In fact, *ilvA* from *C. glutamicum* produced the best in terms of 2MB despite its inhibition by isoleucine. It has also been reported that in isoleucine production, *tdcB* from *E. coli* can produce as much as ten-fold better than *ilvA* from *C. glutamicum* in a *C. glutamicum* strain (Guillouet et al. [@CR15]), and we clearly did not see that effect here. This information serves to highlight one aspect of how much 2MB production differs from isoleucine production.

The ultimate goal is to produce higher alcohol biofuels such as 2MB directly from plant biomass, including cellulose and hemicellulose. First, the production of 2MB must be improved by reducing the alcohol side products, especially the 1-propanol production that becomes prominent after the growth phase. At first glance, it seems this is just another obstacle for metabolic engineering to overcome; however, 1-propanol and isobutanol are formed using the KDC and ADH necessary for 2MB production, and isobutanol production is also aided by overexpression of the AHAS enzyme. From this, it becomes apparent that simple metabolic engineering strategy can do only so much to reduce these side products. Since this becomes an issue of substrate competition with both AHAS and KDC, a protein engineering approach appears necessary.

In this first attempt at production of 2MB from a renewable feedstock, the main challenge addressed was that of precursor balancing. Due to the central role of pyruvate in glucose metabolism, we focused instead on increasing the availability of 2KB for efficient 2MB biosynthesis. This was accomplished by overexpressing key genes in the threonine biosynthetic pathway (*thrABC*) without native transcription regulation and also overexpressing an efficient threonine deaminase to convert the increased threonine to 2KB. Further improvement was obtained by knocking out the competing pathways upstream of 2KB production (Δ*metA*, Δ*tdh*). Combined with the overexpression of the downstream part of isoleucine biosynthesis (*ilvGMCD*), along with the KDC and ADH necessary for conversion of KMV to 2MB, this strategy worked to achieve 1.25 g/L 2MB produced in 24 h.
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